Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Clinical trial NCT05904964 · RECRUITING

Trial details

NCT number: NCT05904964
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HR Positive/HER2 Low Expression Metastatic Breast Cancer

Start date: 2023-07-01
Primary completion: 2028-03-01
Enrollment: 288

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.